Supplementary material to article by F. Giannopoulos et al. “Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-control Study.”

**Fig. S3. Survival analyses.** Number of cases and controls at risk in the respective groups are specified at 0, 2, 4 and 6 years after the index date. The index date was in the period 2010 to 2016. (a) Kaplan–Meier estimates for survival comparing the cases and controls. Patients were censored at first emigration date after index or end of observation period (i.e. 31 December 2016), whichever came first. (b) Kaplan–Meier estimates for survival comparing the methotrexate (MTX)-exposed cases and MTX-unexposed cases. Patients were censored at first emigration date after index or end of observation period (31 December 2016), whichever came first. The Cox proportional hazards regression was adjusted for age group (≤ 40, > 40–≤ 50, > 50–≤ 60, > 60–≤ 70 and > 70 years) and sex at index date. MTX exposure status refers to ever-never exposure in the period from initiation of the Swedish drug registry (i.e. July 2005) to the index date. 95% CI: 95% confidence interval.